Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 137,108,736
  • Shares Outstanding, K 2,624,593
  • Annual Sales, $ 24,384 M
  • Annual Income, $ 1,335 M
  • 60-Month Beta 0.55
  • Price/Sales 5.30
  • Price/Cash Flow 16.60
  • Price/Book 9.89
Trade AZN with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 0.53
  • Number of Estimates 3
  • High Estimate 0.56
  • Low Estimate 0.51
  • Prior Year 0.45
  • Growth Rate Est. (year over year) +17.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.17 +8.28%
on 12/24/20
52.74 -1.10%
on 01/21/21
+2.48 (+4.99%)
since 12/21/20
3-Month
48.17 +8.28%
on 12/24/20
58.08 -10.19%
on 11/11/20
+0.59 (+1.14%)
since 10/21/20
52-Week
36.15 +44.29%
on 03/16/20
64.94 -19.68%
on 07/20/20
+1.36 (+2.68%)
since 01/21/20

Most Recent Stories

More News
China Jo-Jo Drugstores Hosts the First Suppliers Conference in China

, /PRNewswire/ -- Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and...

AZN : 52.41 (+0.33%)
PFE : 36.26 (-0.66%)
CJJD : 1.1800 (+5.36%)
AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer

AstraZeneca's (AZN) Enhertu gets EU approval for metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens.

ALKS : 21.29 (-4.49%)
ALXN : 158.32 (+0.37%)
AZN : 52.41 (+0.33%)
MRK : 81.19 (-1.54%)
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $52.24, moving -0.63% from the previous trading session.

AZN : 52.41 (+0.33%)
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock Up

Gritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises.

AZN : 52.41 (+0.33%)
PFE : 36.26 (-0.66%)
MRNA : 133.14 (+6.39%)
GRTS : 22.08 (-13.38%)
Thinking about trading options or stock in Alibaba, General Electric, AstraZeneca, Nio, or Blink Charging?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, GE, AZN, NIO, and BLNK.

AZN : 52.41 (+0.33%)
BLNK : 46.87 (+4.23%)
BABA : 259.44 (-2.28%)
GE : 11.15 (-2.11%)
NIO : 57.63 (-0.14%)
Grifols (GRFS) to Begin Study on Plasma-Derived COVID-19 Drug

Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.

AZN : 52.41 (+0.33%)
PFE : 36.26 (-0.66%)
MRNA : 133.14 (+6.39%)
GRFS : 19.17 (-0.52%)
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer

AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.

ALXN : 158.32 (+0.37%)
AZN : 52.41 (+0.33%)
MRK : 81.19 (-1.54%)
NVAX : 127.46 (+1.93%)
Top Analyst Reports for Visa, T-Mobile & Union Pacific

Top Analyst Reports for Visa, T-Mobile & Union Pacific

V : 205.62 (-0.19%)
UNP : 209.13 (-4.15%)
TMUS : 130.13 (-1.64%)
MMM : 170.52 (+0.18%)
LOW : 173.73 (+0.78%)
AZN : 52.41 (+0.33%)
Dr. Reddy's (RDY) to Begin Phase III Study on Sputnik Vaccine

Dr. Reddy's (RDY) receives approval from the DCGI to conduct a phase III study on the Sputnik V vaccine for the treatment of COVID-19 in India.

AZN : 52.41 (+0.33%)
RDY : 68.57 (-1.54%)
PFE : 36.26 (-0.66%)
MRNA : 133.14 (+6.39%)
AstraZeneca (AZN) Gets EU Nod for Improved Imfinzi Dosing

AstraZeneca's (AZN) four-week, fixed-dose regimen (1500 mg) of Imfinzi will reduce patients's medical visits by half, thereby improving patent convenience.

AZN : 52.41 (+0.33%)
PFE : 36.26 (-0.66%)
MRK : 81.19 (-1.54%)
BMY : 64.32 (-2.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

3rd Resistance Point 53.37
2nd Resistance Point 53.01
1st Resistance Point 52.63
Last Price 52.41
1st Support Level 51.88
2nd Support Level 51.52
3rd Support Level 51.14

See More

52-Week High 64.94
Fibonacci 61.8% 53.94
Last Price 52.41
Fibonacci 50% 50.55
Fibonacci 38.2% 47.15
52-Week Low 36.15

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar